{"entity":{"type":"insider","cik":"0001352546","url":"/insider/0001352546","json_url":"/insider/0001352546.json","name":"Flynn James E","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":1449,"n_filings":269,"first":"2006-02-08","last":"2026-03-02","span_basis":"filed_date"},"name_variants":[{"name":"Flynn James E","source":"filing","n_filings":269,"first_seen":"2006-02-08","last_seen":"2026-03-02"}],"transactions":[{"id":6136162,"accession":"0001193805-26-000205","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-26-000205","line_url":"/filing/0001193805-26-000205","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Larimar Therapeutics, Inc.","issuer_ticker":"LRMR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt HIF, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P.; Deerfield Mgmt L.P.; Deerfield Private Design Fund IV, L.P.; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt IV, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Flynn James E","owner_display_name":"Deerfield Mgmt HIF, L.P.","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000000.0,"shares_display":"5,000,000","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":25000000.0,"total_display":"25,000,000.00","total_whole":"25,000,000","shares_owned_after":6207982.0,"shares_owned_after_display":"6,207,982","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-27","filed_date":"2026-03-02","scope":"insider","n_lines":4},{"id":4579373,"accession":"0001193805-25-001648","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-25-001648","line_url":"/filing/0001193805-25-001648","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Nuvalent, Inc.","issuer_ticker":"NUVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt IV, L.P.; DEERFIELD PARTNERS, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P.; Deerfield Mgmt L.P.; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt HIF, L.P.","owner_display_name":"Flynn James E","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":742574.0,"shares_display":"742,574","price_per_share":95.445,"price_display":"95.44","price_state":"stated","total_value":70874975.43,"total_display":"70,874,975.43","total_whole":"70,874,975","shares_owned_after":8299225.0,"shares_owned_after_display":"8,299,225","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-24","filed_date":"2025-11-24","scope":"insider","n_lines":2},{"id":5143787,"accession":"0001193805-25-001155","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-25-001155","line_url":"/filing/0001193805-25-001155","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Larimar Therapeutics, Inc.","issuer_ticker":"LRMR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; Deerfield Healthcare Innovations Fund, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Mgmt L.P.; Deerfield Mgmt IV, L.P.; Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt III, L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt HIF, L.P.","owner_display_name":"Flynn James E","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9375000.0,"shares_display":"9,375,000","price_per_share":3.2,"price_display":"3.20","price_state":"stated","total_value":30000000.0,"total_display":"30,000,000.00","total_whole":"30,000,000","shares_owned_after":9538945.0,"shares_owned_after_display":"9,538,945","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-07-31","filed_date":"2025-08-04","scope":"insider","n_lines":3},{"id":4426836,"accession":"0001193805-25-000959","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-25-000959","line_url":"/filing/0001193805-25-000959","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"ARS Pharmaceuticals, Inc.","issuer_ticker":"SPRY","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt IV, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.","owner_display_name":"Deerfield Private Design Fund IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":740149.0,"shares_display":"740,149","price_per_share":18.46,"price_display":"18.46","price_state":"stated","total_value":13663150.54,"total_display":"13,663,150.54","total_whole":"13,663,151","shares_owned_after":4887254.0,"shares_owned_after_display":"4,887,254","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-27","filed_date":"2025-07-01","scope":"insider","n_lines":2},{"id":3218003,"accession":"0001193805-24-001348","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001193805-24-001348","line_url":"/filing/0001193805-24-001348","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"ARS Pharmaceuticals, Inc.","issuer_ticker":"SPRY","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Private Design Fund IV, L.P.; Flynn James E; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield Mgmt IV, L.P.","owner_display_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34814.0,"shares_display":"34,814","price_per_share":17.494786867352214,"price_display":"17.49","price_state":"stated","total_value":609063.51,"total_display":"609,063.51","total_whole":"609,064","shares_owned_after":5257329.0,"shares_owned_after_display":"5,257,329","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-12","filed_date":"2024-11-13","scope":"insider","n_lines":4},{"id":3217981,"accession":"0001193805-24-001348","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-24-001348","line_url":"/filing/0001193805-24-001348","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"ARS Pharmaceuticals, Inc.","issuer_ticker":"SPRY","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Private Design Fund IV, L.P.; Flynn James E; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield Mgmt IV, L.P.","owner_display_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":528456.0,"shares_display":"528,456","price_per_share":18.04245197329579,"price_display":"18.04","price_state":"stated","total_value":9534642.0,"total_display":"9,534,642.00","total_whole":"9,534,642","shares_owned_after":5274736.0,"shares_owned_after_display":"5,274,736","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-11","filed_date":"2024-11-13","scope":"insider","n_lines":4},{"id":3243032,"accession":"0001193805-24-001275","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-24-001275","line_url":"/filing/0001193805-24-001275","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Nuvalent, Inc.","issuer_ticker":"NUVL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt L.P.; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt HIF, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E; Deerfield Mgmt IV, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Private Design Fund IV, L.P.","owner_display_name":"Deerfield Mgmt L.P.","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000000.0,"shares_display":"2,000,000","price_per_share":97.75,"price_display":"97.75","price_state":"stated","total_value":195500000.0,"total_display":"195,500,000.00","total_whole":"195,500,000","shares_owned_after":8670512.0,"shares_owned_after_display":"8,670,512","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-22","filed_date":"2024-10-24","scope":"insider","n_lines":2},{"id":3170001,"accession":"0001193805-24-001131","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-24-001131","line_url":"/filing/0001193805-24-001131","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Bicara Therapeutics Inc.","issuer_ticker":"BCAX","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD PARTNERS, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Private Design Fund V, L.P.; Deerfield Mgmt V, L.P.; Deerfield Mgmt L.P.; Flynn James E","owner_display_name":"DEERFIELD PARTNERS, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":70000.0,"shares_display":"70,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":1260000.0,"total_display":"1,260,000.00","total_whole":"1,260,000","shares_owned_after":897587.0,"shares_owned_after_display":"897,587","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-17","filed_date":"2024-09-17","scope":"insider","n_lines":2},{"id":2793026,"accession":"0001193805-24-000360","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001193805-24-000360","line_url":"/filing/0001193805-24-000360#line-5","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"AdaptHealth Corp.","issuer_ticker":"AHCO","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund IV, L.P.; Flynn James E; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt IV, L.P.","owner_display_name":"Deerfield Private Design Fund IV, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":114906.0,"shares_display":"114,906","price_per_share":10.7,"price_display":"10.70","price_state":"stated","total_value":1229494.2,"total_display":"1,229,494.20","total_whole":"1,229,494","shares_owned_after":11528863.0,"shares_owned_after_display":"11,528,863","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-12","filed_date":"2024-03-12","scope":"insider"},{"id":2793022,"accession":"0001193805-24-000360","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-24-000360","line_url":"/filing/0001193805-24-000360","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"AdaptHealth Corp.","issuer_ticker":"AHCO","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund IV, L.P.; Flynn James E; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt IV, L.P.","owner_display_name":"Deerfield Private Design Fund IV, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":182607.0,"shares_display":"182,607","price_per_share":11.021246940150158,"price_display":"11.02","price_state":"stated","total_value":2012556.84,"total_display":"2,012,556.84","total_whole":"2,012,557","shares_owned_after":11731809.0,"shares_owned_after_display":"11,731,809","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-11","filed_date":"2024-03-12","scope":"insider","n_lines":2},{"id":2793010,"accession":"0001193805-24-000360","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-24-000360","line_url":"/filing/0001193805-24-000360","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"AdaptHealth Corp.","issuer_ticker":"AHCO","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund IV, L.P.; Flynn James E; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt IV, L.P.","owner_display_name":"Deerfield Private Design Fund IV, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52487.0,"shares_display":"52,487","price_per_share":10.929420427915483,"price_display":"10.93","price_state":"stated","total_value":573652.49,"total_display":"573,652.49","total_whole":"573,652","shares_owned_after":11830871.0,"shares_owned_after_display":"11,830,871","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-08","filed_date":"2024-03-12","scope":"insider","n_lines":2},{"id":2505760,"accession":"0001193805-24-000245","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-24-000245","line_url":"/filing/0001193805-24-000245","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Larimar Therapeutics, Inc.","issuer_ticker":"LRMR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund IV, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Mgmt III, L.P.; Deerfield Private Design Fund III, L.P.; Flynn James E; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Mgmt L.P.; Deerfield Mgmt IV, L.P.; Deerfield Healthcare Innovations Fund, L.P.","owner_display_name":"Deerfield Private Design Fund IV, L.P.","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4290617.0,"shares_display":"4,290,617","price_per_share":8.74,"price_display":"8.74","price_state":"stated","total_value":37499992.58,"total_display":"37,499,992.58","total_whole":"37,499,993","shares_owned_after":6151406.0,"shares_owned_after_display":"6,151,406","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-16","filed_date":"2024-02-16","scope":"insider","n_lines":3},{"id":6667585,"accession":"0001193805-22-001817","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001193805-22-001817","line_url":"/filing/0001193805-22-001817","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Oncorus, Inc.","issuer_ticker":"ONCR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Healthcare Innovations Fund, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Mgmt HIF, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Mgmt L.P.; Flynn James E; Deerfield Mgmt III, L.P.; Deerfield Private Design Fund III, L.P.","owner_display_name":"Deerfield Healthcare Innovations Fund, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":138872.0,"shares_display":"138,872","price_per_share":0.27,"price_display":"0.27","price_state":"stated","total_value":37495.44,"total_display":"37,495.44","total_whole":"37,495","shares_owned_after":1156309.0,"shares_owned_after_display":"1,156,309","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-30","filed_date":"2022-12-30","scope":"insider","n_lines":3},{"id":6667581,"accession":"0001193805-22-001817","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193805-22-001817","line_url":"/filing/0001193805-22-001817","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Oncorus, Inc.","issuer_ticker":"ONCR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Healthcare Innovations Fund, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Mgmt HIF, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Mgmt L.P.; Flynn James E; Deerfield Mgmt III, L.P.; Deerfield Private Design Fund III, L.P.","owner_display_name":"Deerfield Healthcare Innovations Fund, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":141753.0,"shares_display":"141,753","price_per_share":0.26,"price_display":"0.26","price_state":"stated","total_value":36855.78,"total_display":"36,855.78","total_whole":"36,856","shares_owned_after":1218134.0,"shares_owned_after_display":"1,218,134","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-29","filed_date":"2022-12-30","scope":"insider","n_lines":3},{"id":6667576,"accession":"0001193805-22-001817","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-22-001817","line_url":"/filing/0001193805-22-001817","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Oncorus, Inc.","issuer_ticker":"ONCR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Healthcare Innovations Fund, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Mgmt HIF, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Mgmt L.P.; Flynn James E; Deerfield Mgmt III, L.P.; Deerfield Private Design Fund III, L.P.","owner_display_name":"Deerfield Healthcare Innovations Fund, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55610.0,"shares_display":"55,610","price_per_share":0.25,"price_display":"0.25","price_state":"stated","total_value":13902.5,"total_display":"13,902.50","total_whole":"13,903","shares_owned_after":1281242.0,"shares_owned_after_display":"1,281,242","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-28","filed_date":"2022-12-30","scope":"insider","n_lines":3},{"id":6563897,"accession":"0001193805-22-001793","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193805-22-001793","line_url":"/filing/0001193805-22-001793","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Oncorus, Inc.","issuer_ticker":"ONCR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund III, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Mgmt L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Mgmt III, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Healthcare Innovations Fund, L.P.; Flynn James E","owner_display_name":"Deerfield Private Design Fund III, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":65090.0,"shares_display":"65,090","price_per_share":0.27,"price_display":"0.27","price_state":"stated","total_value":17574.3,"total_display":"17,574.30","total_whole":"17,574","shares_owned_after":1305999.0,"shares_owned_after_display":"1,305,999","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-27","filed_date":"2022-12-27","scope":"insider","n_lines":3},{"id":6563887,"accession":"0001193805-22-001793","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-22-001793","line_url":"/filing/0001193805-22-001793","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Oncorus, Inc.","issuer_ticker":"ONCR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund III, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Mgmt L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Mgmt III, L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Healthcare Innovations Fund, L.P.; Flynn James E","owner_display_name":"Deerfield Private Design Fund III, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8294.0,"shares_display":"8,294","price_per_share":0.28,"price_display":"0.28","price_state":"stated","total_value":2322.32,"total_display":"2,322.32","total_whole":"2,322","shares_owned_after":1334976.0,"shares_owned_after_display":"1,334,976","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-22","filed_date":"2022-12-27","scope":"insider","n_lines":3},{"id":6142077,"accession":"0001193805-22-001764","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001193805-22-001764","line_url":"/filing/0001193805-22-001764","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Oncorus, Inc.","issuer_ticker":"ONCR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD PARTNERS, L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Mgmt III, L.P.; Deerfield Private Design Fund III, L.P.; Flynn James E; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt L.P.","owner_display_name":"DEERFIELD PARTNERS, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13800.0,"shares_display":"13,800","price_per_share":0.3,"price_display":"0.30","price_state":"stated","total_value":4140.0,"total_display":"4,140.00","total_whole":"4,140","shares_owned_after":1338668.0,"shares_owned_after_display":"1,338,668","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-21","filed_date":"2022-12-21","scope":"insider","n_lines":3},{"id":6142065,"accession":"0001193805-22-001764","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193805-22-001764","line_url":"/filing/0001193805-22-001764#line-6","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Oncorus, Inc.","issuer_ticker":"ONCR","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD PARTNERS, L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Mgmt III, L.P.; Deerfield Private Design Fund III, L.P.; Flynn James E; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt L.P.","owner_display_name":"DEERFIELD PARTNERS, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6562.0,"shares_display":"6,562","price_per_share":0.31,"price_display":"0.31","price_state":"stated","total_value":2034.22,"total_display":"2,034.22","total_whole":"2,034","shares_owned_after":1344812.0,"shares_owned_after_display":"1,344,812","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-20","filed_date":"2022-12-21","scope":"insider"}],"collapsed":true,"next_cursor":"2022-12-20|6142065","ledger_fault":false,"count":{"value":10,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":10,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":10},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001374690","name":"Larimar Therapeutics, Inc.","url":"/issuer/0001374690","role":"Director, Ten percent owner, Other","n_filings":8,"first_seen":"2016-02-11","last_seen":"2026-03-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001861560","name":"Nuvalent, Inc.","url":"/issuer/0001861560","role":"Director, Ten percent owner, Other","n_filings":3,"first_seen":"2022-11-07","last_seen":"2025-11-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001671858","name":"ARS Pharmaceuticals, Inc.","url":"/issuer/0001671858","role":"Ten percent owner","n_filings":2,"first_seen":"2024-11-13","last_seen":"2025-07-01"},{"type":"issuer","type_label":"ISSUER","cik":"0002023658","name":"Bicara Therapeutics Inc.","url":"/issuer/0002023658","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2024-09-17","last_seen":"2024-09-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001725255","name":"AdaptHealth Corp.","url":"/issuer/0001725255","role":"Director, Ten percent owner, Other","n_filings":2,"first_seen":"2018-02-23","last_seen":"2024-03-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001671818","name":"Oncorus, Inc.","url":"/issuer/0001671818","role":"Director, Ten percent owner, Other","n_filings":6,"first_seen":"2020-10-08","last_seen":"2022-12-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001759425","name":"Mirum Pharmaceuticals, Inc.","url":"/issuer/0001759425","role":"Ten percent owner, Other","n_filings":4,"first_seen":"2019-07-24","last_seen":"2022-06-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001835597","name":"PepGen Inc.","url":"/issuer/0001835597","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2022-05-10","last_seen":"2022-05-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001840233","name":"Xilio Therapeutics, Inc.","url":"/issuer/0001840233","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2021-10-28","last_seen":"2021-10-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001863294","name":"DA32 Life Science Tech Acquisition Corp.","url":"/issuer/0001863294","role":"Director, Ten percent owner, Other","n_filings":1,"first_seen":"2021-08-03","last_seen":"2021-08-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001522860","name":"Acutus Medical, Inc.","url":"/issuer/0001522860","role":"Director, Ten percent owner, Other","n_filings":2,"first_seen":"2020-08-12","last_seen":"2021-07-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001850906","name":"Singular Genomics Systems, Inc.","url":"/issuer/0001850906","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2021-06-03","last_seen":"2021-06-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001785530","name":"Werewolf Therapeutics, Inc.","url":"/issuer/0001785530","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2021-05-04","last_seen":"2021-05-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001710072","name":"Edgewise Therapeutics, Inc.","url":"/issuer/0001710072","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2021-03-30","last_seen":"2021-03-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001831363","name":"Terns Pharmaceuticals, Inc.","url":"/issuer/0001831363","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2021-02-09","last_seen":"2021-02-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001126234","name":"LUMOS PHARMA, INC.","url":"/issuer/0001126234","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2021-01-08","last_seen":"2021-01-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001534133","name":"GRAYBUG VISION, INC.","url":"/issuer/0001534133","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2020-10-01","last_seen":"2020-10-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001528115","name":"Annexon, Inc.","url":"/issuer/0001528115","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2020-07-28","last_seen":"2020-07-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001787400","name":"Nkarta, Inc.","url":"/issuer/0001787400","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2020-07-14","last_seen":"2020-07-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001733294","name":"Generation Bio Co.","url":"/issuer/0001733294","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2020-06-16","last_seen":"2020-06-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001628171","name":"Revolution Medicines, Inc.","url":"/issuer/0001628171","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2020-02-18","last_seen":"2020-02-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001490978","name":"Schrodinger, Inc.","url":"/issuer/0001490978","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2020-02-10","last_seen":"2020-02-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001701541","name":"Black Diamond Therapeutics, Inc.","url":"/issuer/0001701541","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2020-02-03","last_seen":"2020-02-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001661998","name":"Homology Medicines, Inc.","url":"/issuer/0001661998","role":"Director, Ten percent owner, Other","n_filings":6,"first_seen":"2018-04-04","last_seen":"2020-01-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001759138","name":"Cabaletta Bio, Inc.","url":"/issuer/0001759138","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2019-10-30","last_seen":"2019-10-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001703647","name":"Frequency Therapeutics, Inc.","url":"/issuer/0001703647","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2019-10-07","last_seen":"2019-10-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001557746","name":"Aclaris Therapeutics, Inc.","url":"/issuer/0001557746","role":"Ten percent owner","n_filings":4,"first_seen":"2019-05-13","last_seen":"2019-07-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001642545","name":"ShockWave Medical, Inc.","url":"/issuer/0001642545","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2019-03-11","last_seen":"2019-03-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001346302","name":"XERIS PHARMACEUTICALS INC","url":"/issuer/0001346302","role":"Ten percent owner, Other","n_filings":5,"first_seen":"2018-06-27","last_seen":"2019-02-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001655759","name":"ARVINAS INC.","url":"/issuer/0001655759","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2018-10-01","last_seen":"2018-10-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001434418","name":"CONSTELLATION PHARMACEUTICALS INC","url":"/issuer/0001434418","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2018-07-23","last_seen":"2018-07-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001012477","name":"AVADEL PHARMACEUTICALS PLC","url":"/issuer/0001012477","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2018-06-25","last_seen":"2018-06-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001730430","name":"Kiniksa Pharmaceuticals, Ltd.","url":"/issuer/0001730430","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2018-05-31","last_seen":"2018-05-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001567892","name":"Mallinckrodt plc","url":"/issuer/0001567892","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2018-05-10","last_seen":"2018-05-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001124105","name":"CATALYST BIOSCIENCES, INC.","url":"/issuer/0001124105","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2018-03-08","last_seen":"2018-03-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001359931","name":"PROTEON THERAPEUTICS INC","url":"/issuer/0001359931","role":"Director, Ten percent owner, Other","n_filings":2,"first_seen":"2014-10-27","last_seen":"2017-12-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001649904","name":"RHYTHM PHARMACEUTICALS, INC.","url":"/issuer/0001649904","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2017-10-10","last_seen":"2017-10-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001588972","name":"Recro Pharma, Inc.","url":"/issuer/0001588972","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2017-06-09","last_seen":"2017-06-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001333493","name":"eHealth, Inc.","url":"/issuer/0001333493","role":"Ten percent owner, Other","n_filings":12,"first_seen":"2014-08-05","last_seen":"2017-04-27"},{"type":"issuer","type_label":"ISSUER","cik":"0000764579","name":"CAS MEDICAL SYSTEMS INC","url":"/issuer/0000764579","role":"Ten percent owner, Other","n_filings":3,"first_seen":"2015-01-05","last_seen":"2017-01-26"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001352546","retrieved_at":"2026-08-26T20:12:48+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}